Salarius cuts merger valuation from $4.6M to $2.31M; legacy holders drop to 7.6%

Decoy Therapeutics Inc.

Parent Valuation reduced to $2.31M, down from $4.6M in original Jan 2025 merger agreement.
Legacy Salarius stockholders retention cut to 7.6% from 14.1%; Decoy holders rise to 92.4%.
Exchange ratio change adds ~17M more shares to Decoy stockholders at closing.
Series A Preferred includes one-year anti-dilution protection and Nasdaq conversion restrictions.
Automatic conversion conditioned on Nasdaq listing approval and stockholder vote per Rule 5635.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.